52 search results for: disease control
Assessing EoE: Assessing Symptoms in Patients With EoE
Join Dr. Nirmala Gonsalves as she reviews symptoms of EoE and tools to assess symptoms in patients with EoE.
Assessing EoE: Measuring Quality of Life in Patients With EoE
Join Dr. Nirmala Gonsalves as she reviews some of the tools to assess quality-of-life outcomes in patients with EoE.
The Need for Maintenance Therapy in EoE
Hear Dr. Evan Dellon outline the benefits of maintenance therapy in EoE and the importance of an individualized treatment approach for each patient.
Partnering With Patients: Scores That Matter in CRSwNP
Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life
Beyond Clinical Control: Targeting Type 2 Inflammation for Improved Patient Outcomes
Prof Alan Irvine presents the latest clinical and real-world evidence supporting the potential for disease modification in atopic dermatitis, at EADV 2025.
ERS-ISIAN 2025 | Treatable Traits in CRSwNP
Join Prof. Sietze Reitsma for an insightful presentation that will delve into identifying and leveraging key characteristics to optimize patient management and treatment outcomes.
Loss of Smell is a Key Symptom of CRSwNP
Learn how loss of smell in CRSwNP is a key symptom for both patients and providers.
Understanding Barriers to Advanced Systemic Therapy in AD
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025
Early Intervention May Have the Potential to Alter the Trajectory of Atopic Dermatitis
Dr. Lawrence Eichenfield discusses the meaning of "early intervention" and its potential implications in atopic dermatitis.
Cumulative Impact of Uncontrolled Atopic Dermatitis: Skin Inflammation as the Tip of the Iceberg
Prof Jean-David Bouaziz describes the multifaceted burden of atopic dermatitis, beyond what can be seen on the skin, at EADV 2025.
Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson outlines why early, targeted control of type 2 inflammation may modify the course of atopic dermatitis by addressing upstream drivers of barrier dysfunction, dysbiosis, and itch.
ADVENT On Air | Best Practice for CSU - Perspectives from Allergy and Dermatology
Join allergist Dr. Nicole Chase and dermatologist Dr. Jason Hawkes as they dispel common myths in the management of chronic spontaneous urticaria (CSU). They offer practical, empathetic strategies to move beyond unnecessary diagnostics and delays, focusing instead on urgent treatment escalation and effective management to reduce the profound burden of uncontrolled CSU on patients.
